• shareshare
  • link
  • cite
  • add
Publication . Article . 2009

Comparison of Nucleoside Reverse Transcriptase Inhibitor Use as Part of First-Line Therapy in a Serbian and a UK HIV Clinic

Gordana Dragovic; CJ Smith; Djordje Jevtovic; Margaret Johnson; Jovan Ranin; Dubravka Salemovic; Mike Youle;
Published: 01 Oct 2009 Journal: HIV Clinical Trials, volume 10, pages 306-313 (issn: 1528-4336, eissn: 1945-5771, Copyright policy )
Publisher: Informa UK Limited
AbstractBackground: Use of dideoxynucleoside reverse transcriptase inhibitors (dNRTIs) may lead to increased mitochondrial toxicity. We compared nucleoside reverse transcriptase inhibitor (NRTI) use as part of antiretroviral therapy (ART) in two HIV clinics: one in a low-middle income (HIV Centre Belgrade [HCB], Serbia) and one a high income (ICDC, Royal Free Hospital, London, UK) country. Methods: Antiretroviralnaive patients starting ART from 2003 to 2005 were included. Specifi c NRTIs were compared between centers, focusing on dNRTI use. Kaplan-Meier estimates of the percentage of patients making changes to their NRTI backbone (a) for any reason or (b) for mitochondrial toxicity (peripheral neuropathy, pancreatitis, lactic acidosis) were calculated. Results: Of 287 HCB patients, 89 (31.0%) received didanosine (ddI)-containing, 39 (13.6%) stavudine (d4T)-containing, and 39 (13.6%) ddI+d4Tcontaining regimens; for 539 ICDC patients, these were 18 (3.3%), 66 (12.2%), and 0 (0.0%), respectively (p < .0001)....
Subjects by Vocabulary

Microsoft Academic Graph classification: Internal medicine medicine.medical_specialty medicine Reverse transcriptase Nucleoside Reverse Transcriptase Inhibitor Acquired immunodeficiency syndrome (AIDS) medicine.disease business.industry business Didanosine medicine.drug Stavudine Toxicity Lactic acidosis Mitochondrial toxicity Virology

Medical Subject Headings: virus diseases


Pharmacology (medical), Infectious Diseases

Download from
HIV Clinical Trials
Article . 2009
Providers: Crossref